COMMUNIQUÉS West-GlobeNewswire

Scilex Holding Company Strengthens Board of Directors with Appointment of Two Highly Accomplished Pharmaceutical and Biotechnology Executives, Scott Whitcup, M.D. and Elizabeth Czerepak

30/09/2019 - 13:00

PALO ALTO, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex) today announced that it appointed Scott M. Whitcup, M.D. as lead independent director to its Board of Directors in May of this year. [...]

FibroGen Announces Publication in the Lancet Respiratory Medicine of Positive Pamrevlumab Efficacy and Safety Data for the Praise Phase 2 Study in Idiopathic Pulmonary Fibrosis

30/09/2019 - 13:00

-- Novel Human Antibody Targets CTGF, A Central Mediator in Fibrosis -- SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced publication in The Lancet Respiratory Medicine of [...]

Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy at the AHA 2019 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation

30/09/2019 - 13:00

SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in transthyretin (TTR) [...]

Kalos Therapeutics, Inc., Oncology Pharmaceuticals and NanoSmart Pharmaceuticals, Inc., Combination Therapy Offers the Potential of a Safer and More Effective Approach to a Wide Variety of Cancer Treatments

30/09/2019 - 12:30

SAN FRANCISCO, CA, Sept. 30, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Oncology Pharma (OTCPK: ONPH) is pleased to announce that Kalos Therapeutics' lead compound, KTH-222, can produce a reduction in the attachment of [...]

Precision BioSciences Appoints Nicholas Riddle, MB, BChir, PhD, as Vice President, Financial Strategy and Investor Relations

30/09/2019 - 12:30

DURHAM, N.C., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life through the application of its pioneering, proprietary [...]

BeiGene Announces Clinical Data on Tislelizumab and Pamiparib Presented at the European Society for Medical Oncology (ESMO) Congress 2019

30/09/2019 - 12:00

CAMBRIDGE, Mass. and BEIJING, China, Sept. 30, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]

Ambu A/S: Financial Diary

30/09/2019 - 10:18

Ambu Financial Diary 2019/20 and 2020/21 Attachment Company Announcement no 16 2018_19

MacroGenics Presents Margetuximab Data in Gastroesophageal Cancer at the ESMO 2019 Congress

30/09/2019 - 09:20

ROCKVILLE, MD, Sept. 30, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for [...]

ASLAN Pharmaceuticals and Bukwang Pharmaceutical Establish a Joint Venture, JAGUAHR Therapeutics, to Develop Novel Immuno-Oncology Therapies

30/09/2019 - 08:35

- ASLAN spins out pre-clinical assets in joint venture with Bukwang to form JAGUAHR Therapeutics with Bukwang investing up to US$5 million - ASLAN and Bukwang will co-own new entity to develop novel pre-clinical AhR [...]

Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment with Alecensa

30/09/2019 - 08:30

Efficacy of Alecensa® (alectinib) in people identified to have ALK-positive non-small cell lung cancer using liquid biopsy is consistent with efficacy in those identified by tissue analysis in the pivotal Phase III ALEX [...]

NEOVACS ANNOUNCES APPOINTMENT OF VINCENT SERRA AS CHIEF EXECUTIVE OFFICER

30/09/2019 - 08:30

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES APPOINTMENT OF VINCENT SERRA AS CHIEF EXECUTIVE OFFICER Paris & Boston, September 30, 2019 – 08h30am CEST - Neovacs (Euronext Growth Paris: ALNEV), a [...]

NÉOVACS ANNONCE LA NOMINATION DE VINCENT SERRA EN QUALITÉ DE DIRECTEUR GÉNÉRAL

30/09/2019 - 08:30

COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE NÉOVACS ANNONCE LA NOMINATION DE VINCENT SERRA EN QUALITÉ DE DIRECTEUR GÉNÉRAL Paris et Boston, le 30 septembre 2019 – 08h30 CEST - Néovacs (Euronext [...]

Aino Health AB (publ): Aino Health signs cooperation agreement with Monetra Oulu Oy

30/09/2019 - 08:15

Aino Health and Monetra Oulu Oy have signed a cooperation agreement in Finland where Monetra Oulu Oy will sell all of Aino’s services and connected implementation services. This cooperation supports Aino’s expansion [...]

Dova Pharmaceuticals to be Acquired by Swedish Orphan Biovitrum AB (Sobi)

30/09/2019 - 08:00

Consideration of up to $29.00 per share includes $27.50 per share in upfront cash and an additional $1.50 per share upon regulatory approval of DOPTELET ® for chemotherapy-induced thrombocytopenia (CIT) as a Contingent [...]

OSE Immunotherapeutics Presents New Preclinical Data on its Novel Bispecific Checkpoint Inhibitor (BiCKI®) Platform Targeting PD-1 and Cytokines to Overcome Tumor Resistance to Checkpoint Inhibitor Blockade

30/09/2019 - 08:00

New data presented at the International Cancer Immunotherapy Conference (CICON) NANTES, France, Sept. 30, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Euronext: OSE) presented new data on its [...]

SPINEWAY : Spineway réalise une augmentation de capital de 1,3 M€

30/09/2019 - 08:00

Spineway réalise une augmentation de capital de 1,3 M€ SPINEWAY annonce la réalisation d’une augmentation de capital avec suppression du droit préférentiel de souscription au profit de la société d’investissements [...]

Change in number of shares and votes in Saniona AB (publ)

30/09/2019 - 08:00

PRESS RELEASE September 30, 2019 During September, the registered number of shares and votes in Saniona AB (publ) (“Saniona”) has increased due to conversion of convertible notes issued pursuant to the convertible notes [...]

Valneva Completes Recruitment for Phase 2 Studies of its Lyme Disease Vaccine Candidate VLA15

30/09/2019 - 07:30

Valneva Completes Recruitment for Phase 2 Studies of its Lyme Disease Vaccine Candidate VLA15 Saint-Herblain (France), September 30, 2019 – Valneva SE (“Valneva” or “the Company”), a biotech company developing and [...]

Valneva: Recrutement terminé pour les études de Phase 2 du candidat vaccin contre la maladie de Lyme VLA15

30/09/2019 - 07:30

Valneva: Recrutement terminé pour les études de Phase 2 du candidat vaccin contre la maladie de Lyme VLA15 Saint-Herblain (France), 30 septembre 2019 –Valneva SE (“Valneva” ou “le Groupe”), société de biotechnologie [...]